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Abstract
Background: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as
salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad
performance status.
Case presentation: We tried palliative chemotherapy with daily low dose oral cyclophosphamide
with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide
(CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and
progression after second line with topotecan.
The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65
months without side effects. She was well during the chemotherapy and lived a normal working and
social life.
Conclusion: We think that use of low dose of oral CTX should be investigated further as a
strategy against tumour progression after standard chemotherapy in patients who are platinum
resistant with poor performance status.
Background
Ovarian cancer remains the most common cause of death
from a gynaecologic malignancy. In 2005, it is estimated
that over 22,000 women will develop ovarian cancer and
16,210 will die as a result [1].
Current treatment of ovarian cancer entails a combination
of surgery and chemotherapy. Currently, 1st-line chemo-
therapy consists of a combination of carboplatin and
paclitaxel to which approximately 80% of women
respond [2].
However, despite aggressive surgery and chemotherapy,
more than 80% of patients will relapse and will then be
treated with second line chemotherapy with objective
responses in about 20% of patients and even lower per-
centages of complete responses. This is why the main goal
of second and third line chemotherapy is palliative care
with the aim to prolong time to progression and to
improve quality of life.
Several chemotherapeutic regimens have been used as sin-
gle agents in phase II trials with patients previously treated
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with cisplatin including paclitaxel, topotecan, liposomal
doxorubicin, gemcitabine and oxaliplatin, showing objec-
tive response rates ranging from 10–50% and different
toxicity profiles [3].
Many factors play a role when choosing a drug, such as
patient compliance, toxicity of previous treatments and
treatment costs. Because, at present there are no parame-
ters to predict response to second or third line chemother-
apy, the need for less toxic and more efficacious
outpatient chemotherapeutic regimens as salvage therapy
for advanced ovarian carcinoma is significant.
Recent experimental studies have shown that certain cyto-
toxic agents, when administered at low and frequent
doses are more effective in targeting tumour endothelium
than large single bolus doses followed by long rest peri-
ods. This is because intra-tumoural vascular endothelial
cells, in contrast to the endothelium of quiescent mature
blood vessels of normal adult tissues, proliferate rapidly
and are vulnerable to cytotoxic agents. However, the long
interval between cycles of conventional chemotherapy
permits the survival and re-growth of a small number of
endothelial cells, allowing tumour angiogenesis to persist.
Continuous, low-dose chemotherapy, on the other hand,
enhances the anti-angiogenic effect of some cytotoxic
agents and may also enhance pro-apoptotic effect in both
dividing tumour cells and endothelial cells. A further
advantage in the use of continuous low-dose chemother-
apy is that it minimises the toxic effects of drugs, allowing
more combinations of potentially synergistic selective
inhibitors of angiogenesis. The use of dosing regimens
that involve the frequent administration of small doses of
drugs without extended rest periods has been termed
"metronomic" or "high time" chemotherapy [4]. For these
reasons we evaluated the clinical efficacy and tolerance of
metronomic chemotherapy as salvage therapy in a young
patient with advanced ovarian carcinoma platinum resist-
ance and bad performance status.
Case presentation
In January 2001 a 36 year old woman, nulliparous,
menarche at 13 years with a regular cycle came to our
Institution because of abdominal pain and increase of
abdominal volume. Serum tumour marker tests revealed
abnormally high levels of CA-125 (182 IU/ml), but nor-
mal levels of CA-19-9 (20,68 IU/ml), CA 15-3 (16 IU/ml)
and CEA (1.1 ng/ml). Ultrasound scan (US) and Compu-
ter tomography (CT) of the pelvis was done at our surgical
department and revealed a moderate amount of ascites
and a conglomeration of the bowel [Fig 1].
Explorative laparotomy revealed one litre of ascites, dif-
fuse peritoneal carcinomatosis and a solid tumour origi-
nating from the ovary that formed a mass with extensive
adhesions to the uterus, sigmoid colon, and rectum in the
pouch of Douglas. There were also numerous metastatic
tumours with a diameter of about 3 cm in the greater
omentum and the retroperitoneum. Based on these find-
ings, we decided to only perform biopsy of the tumour.
Pathologic examination revealed poorly differentiated
serous adenocarcinoma arising from the ovary, FIGO
stage IIIC
After surgery, six courses of chemotherapy with paclitaxel
(175 mg/m2) and carboplatin (CBDCA: AUC 5) were
given every 3 weeks.
At the end of chemotherapy a re-evaluation of the situa-
tion by CT scan and serum marker CA 125 (102 IU/ml)
showed no response to therapy. For this reason we started
with a second line of chemotherapy with topotecan (1,5
mg/m2) for 5 days every 3 weeks. Unfortunately, fifteen
days from the first cycle of chemotherapy the patient
underwent surgery again due to an intestinal occlusion.
The second laparotomy showed that the pelvis and the
abdomen were completely obstructed by a tumour mass
that incorporated the bowel with widespread peritoneal
carcinomatosis of diaphragmatic peritonetoneum and on
liver surface. This situation with an increase of serum
marker Ca 125 (300 IU/ml) showed a clear progression of
the disease. Given the extension we decided to perform
only a colostomy.
Even if the patient only had one cycle of second line
chemotherapy, it was not possible to verify response to
further treatment with topotecan, because of the general
Computer tomography (CT) scan of advanced ovarian can- cer before treatment showing conglomeration of the bowel Figure 1
Computer tomography (CT) scan of advanced ovarian can-
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deterioration with marked weight loss and anaemia grade
2 (classification by the NCI-CTC).
After thorough discussion with the patient, informed con-
sent was obtained and further salvage chemotherapy was
started in August 2001. The regimen of a palliative chem-
otherapy was oral cyclophosphamide (50 mg) every day
plus support therapy with epoetin alpha (10000 IU) every
day plus vitamins.
Even if evaluation with CT scan and serum marker Ca 125
(90 IU/ml), 3 months after colostomy, showed stabiliza-
tion of the disease, surprisingly, the patient improved
with disappearance of anaemia and weight increase.
For 65 months after the diagnosis of ovarian cancer FIGO
stage IIIC platinum resistant the patient continued the
chemotherapy with oral cyclophosphamide (50 mg)
every day plus vitamins without side effects. She had a sta-
bilization of disease [Fig 2] with a normal blood exams,
normal liver and kidney function tests, stabilization of
serum marker Ca 125 (50 IU/ml) and a good performance
status (ECOG = 0). In fact she was well and lived a normal
working and social life during chemotherapy.
In July 2006 the patient came to our institution because of
bladder haemorrhage. We performed a cystoscopy that
showed external compression of the bladder with an
internal formation of the bladder bottom which bled eas-
ily. The biopsy showed a carcinoma of ovarian origin that
revealed a progression of disease.
Unfortunately, the patient died from a severe bladder
haemorrhage before trying an other palliative chemother-
apy line.
Discussion
Despite advances in ovarian cancer chemotherapy regi-
mens, there is a high rate recurrence. Second-line ovarian
cancer therapy often aims at prolonging survival and time
to symptom recurrence. When disease progression or
recurrence occurs after primary chemotherapy, choice of
subsequent therapy must be individualized.
Due to poor response rates with repeat dosing with plati-
num agents, second-line treatment for platinum-resistant
patients usually involves a cytotoxic agent that uses a dif-
ferent mechanism. These agents include topoisomerase
inhibitors (etoposide, topotecan), alkylating agents (ifos-
famide, cyclophosphamide), and other chemotherapies
(doxorubicin, gemcitabine, docetaxel).
At this time, no one drug combination has been shown to
be more efficacious; thus, currently, there is no standard-
of-care salvage treatment recommendation.
Moreover, these agents used at the maximum tolerated
doses may be difficult to administer and are often associ-
ated with severe side-effects, sometimes requiring hospi-
talization.
Not surprisingly, therefore, patient attitudes to toxic
chemotherapy regimens for advanced, platinum resistant,
ovarian cancer are often negative, as the adverse effects of
treatment often seem to outweigh any potential benefits.
Thus, the introduction of newer approaches, having
improved or at least equivalent efficacy but reduced toxic-
ity, are highly desirable. Therapy must be individualized
according to previous response, toxicities, and patient
wishes.
Instead of only using short bursts of toxic MTD chemo-
therapy with long breaks to allow recovery from the harm-
ful side effects, there is now a shift in thinking towards the
view that more compressed or accelerated schedules of
drug administration using much smaller individual doses
than the MTD would be more effective, not only in terms
of reducing certain toxicities, but perhaps even improving
anti tumour effects as well [5]. The most recent refinement
of this concept is called "metronomic" chemotherapy,
which refers to the frequent, even daily, administration of
chemotherapeutics at doses significantly below the MTD,
with no prolonged drug-free breaks.
Metronomic chemotherapy has been defined as a varia-
tion of dose-dense therapy with the important exception
that it is not necessarily dose intense, the cumulative dose
Computer tomography (CT) scan of advanced ovarian can- cer after 65 months after diagnosis showing stable disease  without bowel occlusion due to successful colostomy Figure 2
Computer tomography (CT) scan of advanced ovarian can-
cer after 65 months after diagnosis showing stable disease 
without bowel occlusion due to successful colostomy.BMC Cancer 2007, 7:65 http://www.biomedcentral.com/1471-2407/7/65
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might actually be significantly less or equal to MTD-based
chemotherapy, thus reducing or perhaps even eliminating
in some cases serious drug-induced toxicities, and hence
the need for growth-factor support [6]. Unlike MTD
chemotherapy that presumably mainly targets (proliferat-
ing) tumour cells, frequent or continuous low-dose chem-
otherapy appears to inhibit preferentially the endothelial
cell activity of the tumours' growing vasculature [7]. The
basis of this surprising selectivity may have a number of
mechanisms.
One is believed to involve inhibition of tumour angiogen-
esis as a result of chemotherapeutic drug targeting of
dividing endothelial cells found in growing tumour-asso-
ciated blood vessel capillaries.
Moreover, human vascular endothelial cells in vitro are
sensitive to the growth inhibiting effects of ultra low con-
centrations of paclitaxel, in contrast to many other normal
cell types or tumour cell types. These effects can be ampli-
fied by long-term, continuous exposure, which can also
result in apoptosis of endothelial cells [8]. Such effects
may be secondary to induction of an endogenous inhibi-
tor of angiogenesis, thrombospondin-1, induced by low-
dose chemotherapy by as yet unknown mechanisms,
rather than direct inhibition of endothelial cell growth, or
survival [9]. In addition, the mobilization, viability and
levels of angiogenesis contributing to circulating endothe-
lial progenitor cells may be strongly suppressed, and in a
sustained manner, by metronomic chemotherapy [10].
Among the numerous preclinical schedules using differ-
ent cytotoxic drugs, the oral and daily low-dose adminis-
tration of cyclophosphamide has been extremely
successful in human prostate and breast cancer xenograft
mouse models. It has also been successful in spontane-
ously arising islet cell pancreatic carcinoma, even when
the treatment is initiated on advanced, late stage bulky
tumours, at least when combined with a targeted anti-ang-
iogenic drug and upfront MTD chemotherapy [11,12].
This efficacy is accompanied by absent or low-grade toxic-
ity on tissues otherwise highly sensitive to the respective
regimen of the same drug.
For these reasons we used oral daily low-dose cyclophos-
phamide for our patient, who because of her bad perform-
ance status was against undergoing another traditional
line of chemotherapy. To our knowledge this is the first
report showing the feasibility and the efficacy of cyclo-
phosphamide metronomic chemotherapy for palliative
treatment in advanced epithelial ovarian cancer. This is a
simple therapy that can be administered on an outpatient
basis. Our patient received treatment while performing
normal daily activities at home and a high quality of life
was maintained.
Probably this good clinical response was due to the anti-
angiogenetic effect of cyclophosphamide in blocking pro-
gression of the disease without any toxicity, together with
successful colostomy to improve the general condition of
the patient.
The hypothetical anti-angiogenic and anti-tumour effects
of low-dose metronomic chemotherapy regimens in mice
can be amplified significantly by the concurrent adminis-
tration of a second drug that is highly specific for activated
endothelial cells (e.g., antibodies to vascular endothelial
growth factor receptor-2 [VEGFR-2], PEX [C-terminal
hemopexin-like domain of matrix metalloproteinase
(MMP)-2], anti-VEGF antibodies, and anti-endoglin anti-
bodies). Experiments testing such 'metronomic' schedules
of chemotherapy alone or combined with anti-VEGF com-
pounds showed promising anti-tumour activity [13]. A
recent phase II study evaluated bevacizumab and low
dose 'metronomic' oral cyclophosphamide and found
encouraging response rates in 29 patients (6 partial
response, 17 stable disease, 6 progressive disease) and
progression-free survival at 6 months for 47% of the
patients [14]. Despite the encouraging preliminary results
reported at the 2005 Meeting of the American Society of
Clinical Oncology, this non randomized study presents
several limitations: the small number of patients evalu-
ated, the lack of randomization that does not allow dis-
crimination between the activity of 'metronomic'
chemotherapy and that of the selective anti-VEGF com-
pound; and, finally, the fact that no correlation with
potential markers of angiogenic activity was determined.
Currently no definitive clinical data are available because
no randomized trial comparing conventional versus met-
ronomic with dose-dense schedules has been concluded
[15].
Conclusion
In conclusion, low dose, oral CTX, demonstrated signifi-
cant efficacy in this patient with pre-treated advanced
ovarian cancer. Theoretically, treatments aimed at inhibit-
ing angiogenesis should be chronically administered for a
prolonged period. We think that use of oral CTX should
be investigated further, with or without a second drug that
is highly specific for activated endothelial cells, as a strat-
egy against tumour progression after standard chemother-
apy in patients who are platinum resistant with poor
performance status.
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